

TDF/FTC in Pregnancy Shows No Increase in Adverse Infant Birth Outcomes in US Cohorts Kathryn Rough^{1,2}, George R. Seage III¹, Paige L. Williams^{1,3}, Sonia Hernandez-Diaz¹, Yanling Huo⁴, Ellen G. Chadwick⁵,

¹Department of Epidemiology, Harvard T.H. Chan School of Public Health; ²Division of Pharmacoeconomics, Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health; ⁴Center for Biostatistics and AIDS Research, Harvard T.H. Chan School of Public Health; ⁵Department of Pediatrics, Northwestern University of California Los Angeles; ⁷Department of Pediatrics, University of Colorado School of Medicine at University of Colorado School of Medicine and Division of Infectious Diseases, David Geffen School of Medicine at University of Colorado School of Medic

BACKGROUND

• The IMPAACT PROMISE¹ trial allowed comparison of 2 maternal combination antiretroviral therapies:

TDF/FTC/LPV/r tenofovir disoproxil fumarate, emtricitabine, and ritonavir-boosted lopinavir

VS.

- ZDV/3TC/LPV/r zidovudine. lamivudine. and ritonavir-boosted lopinavir
- Compared to ZDV/3TC/LPV/r, women randomized to TDF/FTC/LPV/r had infants with greater risk of death and twice the risk of being very premature (<34 weeks) or very low birth weight (<1,500g)
- Unclear whether risks are shared by all TDF/FTCbased regimens or how findings may generalize

OBJECTIVE

Using data from two large US-based cohort studies, compare the risk of adverse birth outcomes for infants with in utero exposure to:

TDF/FTC/LPV/r, TDF/FTC/ATV/r, and ZDV/3TC/LPV/r

METHODS

- We included 2 US-based perinatal cohort studies: - IMPAACT P1025
- Dynamic cohort of PHACS SMARTT study
- Included all women with birth outcome information whose first antiretroviral regimen was:

TDF/FTC/LPV/r, TDF/FTC/ATV/r, or ZDV/3TC/LPV/r

- Exposure classified by first regimen during pregnancy
- Infant birth outcomes:
- Preterm (<37 weeks) & very preterm (<34 weeks)
- Low (<2,500g) & very low (<1,500g) birth weight
- Composite adverse & severe adverse outcomes
- (outcomes above plus fetal loss, infant mortality) • Log binomial models fit for regimen comparisons
- Adjusted for race/ethnicity, pre-gestational diabetes, sexually transmitted infections, smoking, and timing of regimen initiation

Figure 1. Study inclusion flowchart




Table 1. Maternal ch

Year of delivery 2002-2004 2005-2008

- 2009-2012
- 2012-2016
- Age at delivery
- 24 years or less
- 25 to 34 years
- 35 years or more
- Education
- Less than high school High school diploma
- College or more Race/ethnicity
- Non-Hispanic White Non-Hispanic Black
- Hispanic
- Other First CD4 in pregnancy
- < 250 cells/mm³
- 250 500 cells/mm³ > 500 cells/mm³
- First HIV RNA in pregnancy < 400 copies/mL
- 400 10,000 copies/mL
- > 10,000 copies/mL
- Pre-pregnancy HIV diagnos Timing of regimen initiation
- Before pregnancy
- Trimester 1 Trimester 2 or 3
- Alcohol use in pregnancy Tobacco use in pregnancy Illicit drug use in pregnancy Pregestational diabetes Hepatitis B/C in pregnancy STI in pregnancy

Table 2. Risk of outcomes by initial regimen

Preterm birth Very preterm birth Low birth weight Very low birth weight Adverse outcome Severe adverse outcome

Risa M. Hoffman⁶, Emily Barr⁷, David E. Shapiro^{3,4}, Kunjal Patel^{1,4}

RESULTS

aracteristics	by	initial	regimen

	TDF/F	TC/LPV/r	TDF/F	TC/ATV/r	ZDV/31	C/LPV/r
	n	= 128	n =	= 539	n =	954
	n	(%)	n	(%)	n	(%)
	0	(0.0)	0	(0.0)	29	(3.0)
	38	(29.7)	92	(17.1)	260	(27.3)
	76	(59.4)	290	(53.8)	554	(58.1)
	14	(10.9)	157	(29.1)	111	(11.6)
	50	(39.1)	136	(25.2)	355	(37.2)
	67	(52.3)	293	(54.4)	473	(49.6)
	11	(8.6)	109	(20.2)	125	(13.1)
	34	(26.6)	188	(34.9)	331	(34.7)
	61	(47.7)	240	(44.5)	427	(44.8)
	33	(25.8)	109	(20.2)	194	(20.3)
	15	(11.7)	44	(8.2)	68	(7.1)
	81	(63.3)	365	(67.7)	611	(64.0)
	30	(23.4)	120	(22.3)	258	(27.0)
	1	(0.8)	9	(22.3)	11	(1.2)
	30	(23.4)	100	(18.6)	194	(20.3)
	47	(36.7)	205	(38.0)	381	(39.9)
	47	(36.7)	225	(41.7)	365	(38.3)
ÿ						
	61	(47.7)	277	(51.4)	281	(29.5)
	33	(25.8)	137	(25.4)	361	(37.8)
	33	(25.8)	122	(22.6)	305	(32.0)
osis	107	(83.6)	470	(87.2)	673	(70.5)
ר						
	58	(45.3)	265	(49.2)	111	(11.6)
	18	(14.1	82	(15.2)	115	(12.1)
	52	(40.6)	192	(35.6)	728	(76.3)
	25	(19.5)	92	(17.1)	182	(19.1)
	30	(23.4)	105	(19.5)	182	(19.1)
у	21	(16.4)	61	(11.3)	115	(12.1)
	1	(0.8)	10	(1.9)	12	(1.3)
/	20	(15.6)	71	(13.2)	99	(10.4)
	36	(28.1)	208	(38.6)	373	(39.1)

Initial antiretroviral regimen during pregnancy							
TDF	/FTC/LPV/r	TDF/	FTC/ATV/r	ZDV/3	BTC/LPV/r		
n	Risk (%)	n	Risk (%)	n	Risk (%)		
27	(21.4)	86	(16.1)	184	(19.5)		
5	(4.0)	26	(4.9)	44	(4.7)		
30	(23.8)	86	(16.2)	175	(18.8)		
1	(0.8)	10	(1.9)	18	(1.9)		
36	(28.1)	127	(23.7)	256	(27.2)		
7	(5.5)	28	(5.2)	51	(5.4)		

Table	3. Risk ra	atios an	d 95% c
initial	antiretro	viral reg	jimen us

	TDF	F/FTC/LPV/r v	s ZDV	/3TC/LPV/r	TDF	TDF/FTC/ATV/r vs ZDV/3TC/LPV/r		TDF/FTC/LPV/r vs TDF/FTC/ATV/r				
	. 21	Crude		Adjusted	Crude Adjusted		Crude		Adjusted			
	RR	95% CI	RR	95% CI	RR	95% CI	RR	95% CI	RR	95% CI	RR	95% CI
Preterm birth	1.10	(0.77, 1.58)	0.95	(0.66, 1.39)	0.83	(0.65, 1.04)	0.76	(0.59, 0.99)	1.33	(0.91, 1.96)	1.23	(0.84, 1.82)
Very preterm birth	0.85	(0.19, 2.11)			1.04	(0.65, 1.68)			0.82	(0.32, 2.08)		
Low birth weight	1.27	(0.90, 1.78)	1.08	(0.76, 1.54)	0.86	(0.68, 1.09)	0.83	(0.64, 1.09)	1.47	(1.02, 2.13)	1.40	(0.97, 2.03)
Very low birth weight	0.41	(0.06, 3.06)			0.97	(0.45, 2.10)			0.42	(0.05, 3.27)		
Adverse outcome	1.03	(0.77, 1.39)	0.90	(0.66, 1.23)	0.87	(0.72, 1.05)	0.83	(0.67, 1.02)	1.18	(0.86, 1.62)	1.11	(0.81, 1.52)
Severe adverse outcome	1.01	(0.47, 2.17)			0.96	(0.61, 1.51)			1.04	(0.47, 2.34)		

Figure 2. Subgroup analyses (unadjusted) for comparison of initial antiretroviral regimen during pregnancy and risk of preterm birth: Risk ratios and 95% confidence intervals

TDF/FTC/LPV/r vs. Z	D١
	-

V/3TC/LPV/r: Crude

TDF/FTC/LPV/r vs. ZDV/3TC/LPV/r: Adjusted

TDF/FTC/LPV/r vs. ZDV/3TC/LPV/r: Initiators only

TDF/FTC/LPV/r vs. ZDV/3TC/LPV/r: Continuers only TDF/FTC/LPV/r vs. ZDV/3TC/LPV/r: First singleton pregnancy TDF/FTC/LPV/r vs. ZDV/3TC/LPV/r: Non-switchers only

TDF/FTC/ATV/r vs. ZDV/3TC/LPV/r: Crude

TDF/FTC/ATV/r vs. ZDV/3TC/LPV/r: Adjusted

TDF/FTC/ATV/r vs. ZDV/3TC/LPV/r: Initiators only


TDF/FTC/ATV/r vs. ZDV/3TC/LPV/r: Continuers only TDF/FTC/ATV/r vs. ZDV/3TC/LPV/r: First singleton pregnancy TDF/FTC/ATV/r vs. ZDV/3TC/LPV/r: Non-switchers only

TDF/FTC/LPV/r vs. TDF
TDF/FTC/LPV/r vs. TDF/F
TDF/FTC/LPV/r vs. TDF/FTC//
TDF/FTC/LPV/r vs. TDF/FTC/AT
TDF/FTC/LPV/r vs. TDF/FTC/ATV/r: First s
TDF/FTC/LPV/r vs. TDF/FTC/ATV/r:

confidence intervals for infant outcomes based on comparisons of sed during pregnancy

F/FTC/ATV/r: Crude -TC/ATV/r: Adjusted ATV/r: Initiators only TV/r: Continuers only singleton pregnancy : Non-switchers only

0.0



Preterm birth



Poster #779

LIMITATIONS

- Some analyses for severe adverse outcomes were underpowered due to a small number of events, especially for comparisons involving TDF/FTC/LPV/r
- Cohorts allowed enrollment late in pregnancy and shortly after delivery, meaning stillbirths and very preterm births may not be well captured
- High rate of switching off TDF/FTC/LPV/r before delivery, yet subgroup analyses restricted to nonswitchers did not alter conclusions
- Lack of information on some outcome predictors (previous preterm delivery, hypertension, and parity) could lead to residual confounding
- Unclear how results will generalize outside the US

CONCLUSIONS

- TDF/FTC/LPV/r use in pregnancy was not associated with adverse birth outcomes when compared to ZDV/3TC/LPV/r or TDF/FTC/ATV/r, though we were underpowered to evaluate severe outcomes
- Differences from PROMISE: dosing, lack of randomization, eligibility criteria, setting, standard of prenatal care
- TDF/FTC/LPV/r was rarely used by pregnant women in two large US-based cohorts
- Given the results of the PROMISE trial and treatment alternatives, it may be advisable to limit the use TDF/FTC/LPV/r in pregnancy
- Our findings support the use of TDF/FTC-based regimens with other protease inhibitors in pregnancy

ACKNOWLEDGMENTS

References

1. Fowler MG, et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med 2016; 375:1726-37

We thank the children & families for their participation in PHACS SMARTT and IMPAACT P1025, and the individuals & institutions involved in the conduct of both studies

National Institutes of Health

Funding: PHACS was supported by the Eunice Kennedy Shriver NICHD with co-funding from NIDA, NIAID, OAR, NIMH, NINDS, NIDOCD, NHLBI, NIDCR, and NIAAA (HD052102, 3 U01 HD052102-05S1, 3 U01 HD052102-06S3, HD052104, 3U01HD052104-06S1). Support for the IMPAACT Network was provided by the NIAID with co-funding from the NICHD and NIMH (UM1AI068632, UM1AI068616, UM1AI106716). KR was additionally supported by grant number T32 AI007433 from NIAID and a training grant from the Pharmacoepidemiology Concentration at the Harvard T.H. Chan School of Public Health.

CONTACT

Kathryn Rough Tel: (617) 525-9388 E-mail: krough@bwh.harvard.edu

Postdoctoral Research Fellow **Division of Pharmacoepidemiology and Pharmacoeconomics** Brigham and Women's Hospital & Harvard Medical School